Brind.

SciBase is seeking to expand its indication via a 510(k) submission while Nevisense already holds CE mark approval in Europe.

Steady: 1 development in the last 24 hours, 1 in the last 7 days Updated 1 hour ago

The latest in this situation

  1. Highmark granted its first positive medical policy for Nevisense, highlighting the U.S. as a key commercial opportunity for SciBase.

How it started

2 reports, 1 independent, last reported Jul 1. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

SciBase is seeking to expand its indication via a 510(k) submission while Nevisense already holds CE mark approval in Europe.

Who's involved

What this event is mainly about
EuropeFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Highmark granted its first positive medical policy for Nevisense, highlighting the U.S. as a key commercial opportunity for SciBase.Sub-event
  2. SciBase filed a 510(k) submission to expand indication, while Nevisense has CE mark in Europe.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story